Related Experiment Video
Updated: Mar 29, 2026
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function
Shunan Ye1, Jianming Zhang2, Jacson Shen1
1Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background And Purpose:
Increased expression of P-glycoprotein (PGP1) is one of the major causes of multidrug resistance (MDR) in cancer, including in osteosarcoma, which eventually leads to the failure of cancer chemotherapy. Thus, there is an urgent need to develop effective therapeutic strategies to override the expression and function of PGP1 to counter MDR in cancer patients.
Experimental Approach:
In an effort to search for new chemical entities targeting PGP1-associated MDR in osteosarcoma, we screened a 500+ compound library of known kinase inhibitors with established kinase selectivity profiles. We aimed to discover potential drug synergistic effects among kinase inhibitors and general chemotherapeutics by combining inhibitors with chemotherapy drugs such as doxorubicin and paclitaxel. The human osteosarcoma MDR cell lines U2OSR2 and KHOSR2 were used for the initial screen and secondary mechanistic studies.
Key Results:
After screening 500+ kinase inhibitors, we identified NVP-TAE684 as the most effective MDR reversing agent. NVP-TAE684 significantly reversed chemoresistance when used in combination with doxorubicin, paclitaxel, docetaxel, vincristine, ET-743 or mitoxantrone. NVP-TAE684 itself is not a PGP1 substrate competitive inhibitor, but it can increase the intracellular accumulation of PGP1 substrates in PGP1-overexpressing cell lines. NVP-TAE684 was found to inhibit the function of PGP1 by stimulating PGP1 ATPase activity, a phenomenon reported for other PGP1 inhibitors.
Conclusions And Implications:
The application of NVP-TAE684 to restore sensitivity of osteosarcoma MDR cells to the cytotoxic effects of chemotherapeutics will be useful for further study of PGP1-mediated MDR in human cancer and may ultimately benefit cancer patients.
Insights
NVP-TAE684 effectively reverses multidrug resistance (MDR) in osteosarcoma by inhibiting P-glycoprotein (PGP1) function. This finding offers a promising strategy to enhance chemotherapy efficacy in cancer patients.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Multidrug resistance (MDR) mediated by P-glycoprotein (PGP1) overexpression is a significant challenge in osteosarcoma chemotherapy.
- This resistance leads to treatment failure and necessitates novel therapeutic strategies to overcome PGP1 function.
Purpose of the Study:
- To identify novel chemical entities capable of reversing PGP1-associated MDR in osteosarcoma.
- To explore synergistic drug combinations of kinase inhibitors and conventional chemotherapeutics.
Main Methods:
- Screening of a library containing over 500 known kinase inhibitors against human osteosarcoma MDR cell lines (U2OSR2, KHOSR2).
- Evaluating synergistic effects of identified inhibitors with chemotherapeutic agents like doxorubicin and paclitaxel.
- Mechanistic studies to elucidate the mode of action of promising compounds.
Main Results:
- NVP-TAE684 was identified as the most potent MDR reversing agent from the kinase inhibitor library.
- NVP-TAE684 significantly restored sensitivity to multiple chemotherapeutics, including doxorubicin and paclitaxel.
- NVP-TAE684 inhibits PGP1 function by stimulating its ATPase activity, increasing intracellular drug accumulation without direct substrate competition.
Conclusions:
- NVP-TAE684 demonstrates potential as a PGP1 inhibitor to overcome MDR in osteosarcoma.
- This agent can re-sensitize osteosarcoma MDR cells to chemotherapy, offering a promising avenue for clinical application.
- Further research into NVP-TAE684 is warranted to benefit cancer patients experiencing PGP1-mediated MDR.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies